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Study For Examining of Evaluation of Blood Pressure (BP) and Investigation of Hypertensive Therapy 
in Postmenopausal Women
Kazuhiro Kobayashi (Department of Nephrology, Saitama Medical School, Moroyama, Iruma -gun, Saitama 
350 -0495, Japan)
Study I: This study was carried out to determine whether non - invasive assessment of cardiovascular system 
discriminates white coat hypertension (WCH). The major reason is the high prevalence of WCH in these subjects 
and it remains uncertain whether WCH is associated with cardiovascular risk. Women were required to be 
naturally menopausal; at least 1 year, but not greater than 5 years, past their menstrual period. Exclusion criteria 
were past history of preeclampsia or eclampsia, severe illness such as myocardial infarction and stroke within 6 
months, having used estrogens or progestins within 3 months, being treated with antihypertensive agents or with 
non pharmacological therapy such as reduction of daily salt, and proteinuric nephropathy. In addition, secondary 
hypertension was excluded as possible. WCH was defined if subjects who had BP more than 150/90 mmHg at office 
had to have both mean systolic and diastolic pressures below 120/80 mmHg at home. Forty - four subjects, mean age 
52 years, recruited from the outpatients clinic, were examined. BPs at office and home, pulse wave velocity (PWV), 
and augmentation index (Aix) were recorded. Left ventricular diameter, septal wall thickness, and left posterior 
wall thickness were assessed by M -mode echocardiography after selecting the measurement section by B -mode 
echocardiography. Twenty patients were diagnosed as having WCH based on the criteria in the trial. We found 
that the patterns of pulse wave were different between subjects with WCH and those with hypertension. The most 
prominent difference was the levels of Aix. In subjects with WCH, Aixs were 25.6±3.8 compared to 38.6±4.5 mmHg 
in those with hypertension. Moreover, PWV of subjects with WCH were 6.05±0.53 and those of with hypertension 
were 8.45±0.72 m/sec (p＜0.01). In addition to these findings, there was a significant association between the values 
of home systolic BP but not those of office systolic BP and PWV, Aix and LV mass index. When we combined the data 
of LV mass index and Aix, white coat hypertension was easily segregated from hypertension. The combination of self 
BP monitoring, echocardiographic data and Aix and PWV would be powerful indicators for treatment of hypertension 
in postmenopausal women.  
Study II: To assess the efficacy of the various classes of antihypertensive drugs in postmenopausal women with 
hypertension. Women were required to be naturally menopausal; at least 1 year, but not greater than 5 years, past 
their menstrual period. Exclusion criteria were past history of preeclampsia or eclampsia, severe illness such 
as myocardial infarction and stroke within 6 months, having used estrogens or progestins within 3 months, and 
proteinuric nephropathy as well as surgically menopausal. 114 women who participated in this study after informed 
consent were obtained. These women were diagnosed as having hypertension based on BP of more than 140/90 mmHg 
at clinic as well as on self - reported BP of more than 130/85 mmHg at home. If both levels of BP were not satisfied 
with the criteria, such patients were also excluded. All antihypertensive medications were withdrawn 6 weeks before 
the initiation of the study. All patients were randomly assigned in equal numbers to the following therapeutic groups; 
A) losartan, 50 mg daily and trichlormethiazide 2 mg twice a week and B) cilnidipine, a calcium channel blocker, 5 
mg and arotinolol, an αβ blocker, 10 mg daily. Three groups were retrospectively segregated according to pulse 
pressure (PP) at the start of the study: Group I (n＝ 24); more than 65 mmHg: Group II (n＝58); below 64 to more 
than 45 mmHg and Group III (n＝32); below 44 mmHg. In Group I, combination therapy with B) reduced systolic BP 
much more compared to that with A) (169±2/88±5 to 133±2/73±5 vs 169±2/88±5 to 149±2/66±5 mmHg, p＜
0.05). On the other hand, in Group III, A) decreased diastolic BP as well as systolic BP (152±2/106±2 to 123±1/78
±1 vs 149±2/107±2 to 129±2/84±1 mmHg, p＜0.05). In Group II, there was no significant difference between two 
antihypertensive regimens. Other three biological markers were not influenced by any type of treatment. PP before 
starting medication of hypertension may be useful for the choice of antihypertensive drugs.
Combining these two studies, it is suggested that evaluation and treatment of hypertensive postmenopausal women 
would be much more investigated than previously and be needed much work to be carried out.  
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うるし，治療中の QOL（Quality of life）の改善をもた

































基準は外来受診時 140/90 mmHg以上 3)かつ家庭血圧












































Table 1. Baseline demographic and clinical characteristics of postmenopausal hypertensive women: white coat hypertensive 











Table 2. Office and home blood pressure, PWV, and Aix in hypertensive and white coat hypertensive postmenopausal women. 
Data expressed in mean±SEM. * means p＜0.05 vs hypertensive women
Fig. 1. The relationship between home systolic blood 
pressure and pulse wave velocity in  hypertensive (non-WCH) 
and white coat hypertensive (WCH) postmenopausal women. 
Circles represent WCH cases, and squares represent non -
WCH cases.
Fig. 2. The relationship between home systolic blood 
pressure and augmentation index (Aix) in hypertensive (non-
WCH) and white coat hypertensive (WCH) postmenopausal 
women. Circles represent WCH cases, and squares represent 
non -WCH cases.
Fig. 3. The relationship between offi ce systolic blood 
pressure and pulse wave velocity in hypertensive (non-WCH) 
and white coat hypertensive (WCH) postmenopausal women. 
Circles represent WCH cases, and squares represent non -
WCH cases.
Fig. 4. The relationship between augmentation index (Aix) 
and LV mass index (LVMi) in hypertensive (non-WCH) and 
white coat hypertensive (WCH) postmenopausal women. 




時の脈圧が 65 mmHg以上の群（第 1群）は 24名で，
治療群 Bの治療薬が治療群 Aに比較して，収縮期血
圧に対する効果が著明であった（Fig. 5 -A，治療群 A 
169±2/88±5から 149±2/66±5 mmHg，治療群 B 
169±2/88±5 か ら 133±2/73±5 mmHg，p＜0.05）．
また治療開始時の脈圧が 44 mmHg以下の群（第 3
群）は 32名で，治療群 Aの治療薬が治療群 Bに比較
して，拡張期血圧に対する効果が著明であった（Fig. 
5 - C，治療群 A 152±10 /106±8 から 132±3 /78±5 
mmHg，治療群 B 153±6 /896±7から 143±3 /87±
5 mmHg，p＜0.05）．治療開始時の脈圧が 45 mmHg
以上 64 mmHg以下の群（第 2群）は 58名と最も多
かったが，治療薬の降圧効果に差はみられなかった
（Fig. 5 - B）．
　治療終了時の降圧目標の達成率は，第 1群では
治療群 Aで 0％，治療群 B で 100％，第 2群では
治療群 Aで 90％，治療群 Bで 85％，第 3群では
治療群 Aで 100％，治療群 Bでも 100％であった，
































Table 3. Echocardiographic parameters in hypertensive and white coat hypertensive postmenopausal women. Data expressed 
in mean ± SEM
Table 4. Baseline demographic and clinical characteristics of postmenopausal hypertensive women  in the two treatment group
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Table 5. Changes in pulse pressure in group 1 (more than 
65 mmHg), group 2 (below 65 to more than 45 mmHg) and 
group 3 (below 45 mmHg). *express p＜0.05 vs baseline 
respectively.
Table 6. Changes in heart rate in group 1 (more than 65 
mmHg), group 2 (below 65 to more than 45 mmHg) and 
group 3 (below 45 mmHg). *p＜0.05 compared to the basal 
values.
(C)
Fig. 5. (A) Effects of combination therapy with losartan 50 
mg daily and trichlormethiazide 2 mg twice a week (● : n＝
12) and with cilnidipine 5 mg and arotinolol 10 mg daily (▲ : n
＝12) on both systolic and diastolic blood pressure of patients 
with wider pulse pressure. * means p＜0.01 compared to 
other thrapeutic group. # means p＜0.01 compared to each 
basal values. (B) Effects of combination therapy with losartan 
50 mg daily and trichlormethiazide 2 mg twice a week (● : n＝
29) and with cilnidipine 5 mg and arotinolol 10 mg daily (▲ : n
＝ 29) on both systolic and diastolic blood pressure of patients 
with standard pulse pressure. # means p＜0.01 compared to 
each basal values.(C) Effects of combination therapy with 
losartan 50 mg daily and trichlormethiazide 2 mg twice a 
week (● : n＝16) and with cilnidipine 5 mg and arotinolol 
10 mg daily (▲ : n＝16) on both systolic and diastolic blood 
pressure of patients with narrow pulse pressure. * means p
＜0.01 compared to other thrapeutic group. # means p＜0.01 
compared to each basal values.  
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クが相対的に低いといったこれらのプロスペクティ















































ち脈圧が 65 mmHg以上で 21％，脈圧が 64から 45 

































































































































 1) Maschio G, Alber ti  D, Janin G, Locatel l i  F,  
Mann J, Montolese M, et al. Effect of the angiotensin 
conver ting -enzyme inhibitor benazepril on the 
progression of chronic renal insufficiency. N Engl J 
Med 1996; 334: 939 -45.
 2) Schillaci G, Verdecchia P, Borgioni C, Ciucci A, 
Porcellati C. Early cardiac changes after menopause. 
Hypertension 1998; 32: 764 -9.
 3) The Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood 
Pressure and the National High Blood Pressure 
Education Program Coordinating Committee.The 
sixth repor t of the joint national committee on 
prevention, detection, evaluation, and treatment of 
high blood pressure. Arch Intern Med 1997; 157: 
2413 -46.
 4) Gueyf fier F, Boutitie F, Boissel JP, Pocock S, 
Coope J, Cutler J, et al. Effect of antihypertensive 
drug treatment on cardiovascular outcomes in 
women and men. A meta - analysis of individual 
59閉経後高血圧の診断方法と治療法の検討
patient data from randomized, controlled trials.The 
INDANA Investigators. Ann Intern Med 1997; 126: 
761 -7.
 5) Perlof f D, Sokolow M, Cowan R. The prognostic 
value of ambulatory blood pressure. JAMA 1983; 
249: 2793 -8.
 6) White WB, Schulman P, McCabe EJ, Dey HM. 
Average daily blood pressure, not of fice blood 
pressure, determines cardiac function in patients 
with hypertension. JAMA 1989; 261: 872 -3.
 7) Hoegholm A, Kristensen KS, Bang LE, Neilsen JW, 
Nielsen WB, Madsen NH. Left ventricular mass and 
geometry in patients with established hypertension 
and white coat hypertension. Am J Hypertens 1993; 
6: 282 -6.
 8) Rudd P, Price MG, Graham LE, Beilstein BA, 
Tarbell SJ, Bacchett P, st al. Conseqeunces of 
worksite hyper tension screening. Dif ferential 
changes in psychosocial function. Am J Med 1986; 
80: 853 -60.
 9) Staessen JA, van der Heijden -Spek JJ, Safar ME, 
Den Hond E, Gasowski J, Fagard RH, et al. Menopause 
and the characteristics of the large arteries in a 
population study. J Hum Hypertens 2001; 15: 511 -8.
10)Nichols WW, O’rourke MF. Wave reflections. In: 
McDonald’s Blood Flow in Arteries. Nichols WW, 
O’rourke MF, editors. London: Oxford University 
Press; 1998. p. 201 -22.
11)Koshy S, Bakris G. Therapeutic approaches to 
achieve desired blood pressure goals: Focus on 
calcium channel blockers. Cardiovasc Drugs Ther 
2000; 14: 295 -301.
12)Brunner HR, Menard J, Waeber B, Burnier M, 
Biollaz J, Nussberger J, et al. Treating the individual 
hyper tensive patient: considerations on dose, 
sequential monotherapy and drug combination. J 
Hypertens 1990; 8: 3 - 11.
13)de Leeuw PW, Notter T, Zilles P. Comparison of 
different fixed antihypertensive combination drugs: 
a double -blind, palcebo -controlled parallel group 
study. J Hypertens 1997; 15: 87 -91.
14)Mancia G, Fallia M, Grappiolo A, Giannattasio C. 
Present and futrue role of combination treatment 
in hyper tension. J Cardiovasc Pharmacol 1998; 
31(suppl 2): S41.
15)Suzuki H, Moriwaki K, Nakamoto H, Sugahara S, 
Kanno Y, Okada H. Blood pressure reduction in the 
morning yields beneficial effects on progression of 
chronic renal insufficiency with regression of left 
ventricular hypertrophy. Clin Exp Hypertens 2002; 
24: 51 -63.
16)Nichols WW, O’rourke MF. principles of recording 
and analysis of arterial waveforms In McDonald’s 
Blood Flow in Arteries. Nichols WW, O’rourke MF, 
editers. London: Oxford University Press;1998; p. 
223 -42. 
17)Nichols WW, O’rourke MF. Sphygmocardiography 
In McDonald’s Blood Flow in Arteries. Theoretical, 
experimental and clinical principles. Nichols WW, 
O’rourke MF, editers. London: Oxford University 
Press;1998; p. 450 -76. 
18) Devereux R, Reichek N. Echocardiographic 
determination of left ventricular mass in man. 
Cicularion 1977; 55: 1325 -50.
19) Asmar R, Zanchetti A. Guidelines for the use of self -
blood pressure monitoring: a summary report of the 
First International Consensus Conference. Groupe 
Evaluation & Measure of the French Society of 
Hypertension. J Hypertens 2000; 18: 493 -508.
20)Verdecchia P, Schillaci G. In Blood Pressure 
Monitoring in Cardiovascular Medicine and 
Therapeutics. White WB, Kaplan NM, editers. 
Totowa New Jersey:  Humana Press; 2001; p.191 -218.
21)Parati G, Pomidossi G, Casadei R, Mancia G. 
Lack of altering to intermittent cuf f inflations 
during noninvasive blood pressure monitoring. 
Hypertension 1985; 7: 597 -601.
22)Appel LI, Stason WB. Ambulatory blood pressure 
monitoring and blood pressure self -measurement in 
the diagnosis and management of hypertension. Ann 
Intern Med 1993; 118: 867 -82.
23)Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, 
Minami N, et al. Proposal of reference values for 
home blood pressure measurement. Prognostic 
criteria based on a prospective obser vation of 
the general population in Ohasama, Japan. Am J 
Hypertens 1997; 10: 409 -18.
24)Perlof f D, Sokolow M, Cowan RM, Juster RP. 
Prognostic value of ambulator y blood pressure 
measurements: further  analyses. J Hypertens 1989; 
7 [Suppl 3]: S3 -10.
25)Pickering TG. Ambulatory monitoring and blood 
pressure variability. London, Science Press; 1991. 
26)Cardil lo C, De Felice F, Campia U, Foll i  G. 
Psychophysiological reactrivity and cardiac 
end -organ changes in white - coat hypertension. 
Hypertension 1993; 21: 836 -44.
27)K u w a j i m a  I ,  M i y a o  M ,  U n o  A ,  S u z u k i  Y,  
Matsushita S, Kuramoto K. Diagnostic values of 
electrocardiography and echocardiography for 
60 小林　和裕
white - coat hypertension in the elderly. Am J Cardiol 
1994; 73: 1232 -4.
28)Sokolow M, Perlof f D, Cowan R. Contribution of 
ambulator y blood pressure to the assessment 
of patients with mild to moderate elevations of 
office blood pressure. Cardiovasc Rev Rep 1980; 1: 
295 -303.
29)Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, 
Devereux R. Relation of arterial pressure waveform 
to  le f t  ventr icu lar  and carot id  anatomy in  
normotensive subjects. J Am Coll Cardiol 1993; 22: 
1873 -80.
30)Marchais SJ, Guerin AP, Pannier BM, Levy BI, 
Safar M, London GM. Wave reflections and cardiac 
hypertorphy in chronic uraemia; influence of body 
size. Hypertension 1993; 22: 876 -83.
31)Shelley JM, Green A, Smith AM, Dudley E, 
Dennerstein L, Hopper J, et al. Relationship of 
endogenous sex hormones to lipids and blood 
pressure in mid -aged women. Ann Epidemiol 1998; 
8: 39 -45.
32)White WB, Koch B, Stimpel M. Usefulness of 
moexipril and hydrochlorothiazide in moderately 
severe essential hypertension. Am J Ther 1997; 4: 
123 -9.
33)Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, 
Nakagawa Y, Umans JG, et al. Safety of losartan 
in hyper tensive patients with thiazide - induced 
hyperuricemia. Kindey Int 1999; 56: 1879 -85.
34)Ogihara T, Yoshinaga K. The clinical efficacy and 
tolerability of the angiotensin II - receptor antagonist 
losartan in Japanese patients with hypertension. 
Blood Press 1996; Suppl 2: 78 -81.
35)Pahor M, Psaty B, Alderman M, Applegate W, 
Williamson J, Cavazzini C, et al. Health outcomes 
associated with calcium antagonists compared with 
other first - line antihypertensive therapies: a meta -
analysis of randomised controlled trials. Lancet 2000; 
356: 1949 -54.
36)Neal B, Mac Mahon S, Chapman N. Ef fects of 
ACE inhibitors, calcium antagonists, and other 
b lood -pressure - lowering dr ugs:  resul ts  of  
prospectively designed overviews of randomised 
trials. Blood Pressure Lowering Treatment Trialists’
Collaboration. Lancet 2000; 356: 1955 -64.
37)Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, 
Brown MJ. Optimisation of antihyper tensive 
treatment by crossover rotation of four major classes. 
Lancet 1999; 353: 2008 -13.
38)Suzuki H, Moriwaki K, Kanno Y, Nakamoto H, 
Okada H, Chen XM. Comparison of the ef fects 
of an ACE inhibitor and alphabeta blocker on the 
progression of renal failure with left ventricular 
hypertrophy: preliminary report. Hypertens Res 
2001; 24: 153 -8.
39)Witteman JCM, Grobbee DE, Kok FJ, Hofman A, 
Valkenburg HA. Increased risk of atherosclerosis in 
women after the menopause. BMJ 1989; 298: 642 -4.
© 2003 The Medical Society of Saitama Medical School
